Oncogene mutation and prognosis in the myelodysplastic syndromes

R A Padua; R R West

Oncogene mutation and prognosis in the myelodysplastic syndromes

Br J Haematol. 2000 Dec;111(3):873-4.

Authors

R A Padua¹, R R West

Affiliation

¹ University of Wales College of Medicine, Heath Park, Cardiff, UK.

PMID: 11122149

Abstract

In a series of myelodysplastic syndrome patients, mutational status (particularly RAS mutation) was found to be prognostic for survival, independently of four previously reported scoring systems (Bournemouth, Sanz, Lille, International).

MeSH terms

Age Factors
Anemia, Refractory / genetics
Anemia, Refractory, with Excess of Blasts / genetics
Anemia, Sideroblastic / genetics
Genes, p53
Genes, ras*
Humans
Leukemia, Myelomonocytic, Chronic / genetics
Mutation
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / mortality
Predictive Value of Tests
Prognosis
Proportional Hazards Models